The facts
Cradle at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- Netherlands
- Founded
- Not found in our sourcesCradle (company blog), Nov 17, 2022
- Last closed-round valuation
- No valuation reported
- What it has shipped
- Has a product
Founders
- Stef van Grieken: CEO and co-founder (no background given on page) (Cradle (company blog), Nov 17, 2022)
Partnership with Hansa Biopharma (Oct 1, 2026), after deals with Lundbeck (Jun 2026) and Bayer (Jan 2026). Oct 1, 2026
What it has built
Shipped, or not yet.
“Has a product” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
Guided Rounds feature
Source3 rounds
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Nov 17, 2022 | Seed | €5.5 million ($5.4m) | Not stated | Index Ventures (co-lead), Kindred Capital (co-lead), Feike Sijbesma, Emily Leproust | Cradle (company blog) |
| Nov 28, 2023 | Series A | $24 million | Not stated | None named | Cradle blog index (company) |
| Nov 26, 2024 | Series B | $73 million | Not stated | IVP (lead), Index Ventures, Kindred Capital | Cradle (company blog) |
Outside checks
What others have found.
- Per Cradle, its design placed second on affinity (8.69 pM) among 23 ranked organizations in the blind, third-party-assayed AIntibody challenge, with results published in Nature Biotechnology (2026; paper page could not be fetched). (Cradle (company blog), describing the AIntibody challenge results, Oct 12, 2026)
Our note: Founded before or in 2022 (exited stealth 2022-11-17); founding year not stated, so it may sit near the 2020 cutoff. Offices in Delft (Netherlands) and Zurich; site says 'Built in Amsterdam & Zurich'. Series B post names Novo Nordisk, J&J Innovative Medicine, Novonesis and Grifols as customers. Its tools engineer proteins for customers; no own clinical pipeline, so no registry entry applies. No 2025-2026 funding round found.
More drug discovery and biology